已核实 DOI PubMed 相关产品: 2

“Dominolike” Barriers Elimination with an Intratumoral Adenosine-Triphosphate-Supersensitive Nanogel to Enhance Cancer Chemoimmunotherapy

Journal 2023 · IF 17.1 · 发表于 2023 年 9 月 28 日
作者: Feiran Zhang,Jingwen Dong,Kan Huang,Bowen Duan,Chenzi Li,Ruoxi Yang,Jing Li,Feng Zhi,Zhanwei Zhou,Minjie Sun
阅读全文 在 PubMed 查看

摘要

Pathophysiological barriers in “cold” tumors seriously limit the clinical outcomes of chemoimmunotherapy. These barriers distribute in a spatial order in tumors, including immunosuppressive microenvironment, overexpressed chemokine receptors, and dense tumor mesenchyme, which require a sequential elimination in therapeutics. Herein, we reported a “dominolike” barriers elimination strategy by an intratumoral ATP supersensitive nanogel (denoted as BBLZ-945@PAC–PTX) for enhanced chemoimmunotherapy. Once it has reached the tumor site, BBLZ-945@PAC–PTX nanogel undergoes supersensitive collapse triggered by adenosine triphosphate (ATP) in perivascular regions and releases BLZ-945 conjugated albumin (BBLZ-945) to deplete tumor-associated macrophages (TAMs). Deeper spatial penetration of shrunk nanogel (PAC–PTX) could not only block CXCR4 on the cell membrane to decrease immunosuppressive cell recruitment but also internalize into tumor cells for tumor-killing and T cell priming. The strategy of “dominolike” barriers elimination in tumors enables immune cell infiltration for a potentiated immune response and offers a high-responsive treatment opinion for chemoimmunotherapy.

本研究中使用的阿拉丁产品

2 款产品在本文中被引用